BioNTech’s oncology pivot comes with a new CEO

BioNTech’s oncology pivot comes with a new CEO is a pharma and life sciences industry update from PharmaVoice. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.

Kelly Bilodeau · 2026-08-14

Guido Oelkers will inherit a deep cancer pipeline, declining vaccine sales and $19 billion to fund the transition.

Source: PharmaVoice